Severe late onset capillary leak syndrome post allo-HSCT successfully treated by bevacizumab: a case report

Song Xue1, Jiaqi Chen2, Yuzhu Shi3

  • 1Department of Bone Marrow Transplant, Beijing Lu Daopei Hospital, Beijing, China.

Frontiers in Medicine
|January 22, 2025
PubMed

This article describes a case of successful management of late-onset CLS occurring after allo-HSCT, employing bevacizumab as the therapeutic agent. Capillary leak syndrome (CLS) represents a critical complication arising from allogeneic hematopoietic stem cell transplantation (allo-HSCT). The prognosis for CLS remains considerably constrained. A targeted therapeutic approach targeting vascular endothelial growth factor (VEGF) offers a novel strategy for the management of CLS.